Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA greenlights Regeneron’s Dupixent for treatment of COPD
FDA approves Dupixent for chronic obstructive pulmonary disease
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Dupixent Gets FDA Approval for COPD
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
STAT
2d
Pharmalittle: We’re reading about CVS under investor pressure, a final warning to J&J and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
2d
Regeneron’s Growth Prospects Bolstered by Dupixent Approval and Promising Oncology Pipeline
Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
2d
Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...
Yahoo Finance
5d
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Dupixent
inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and the program focuses on a specific population of people with evidence of type 2 inflammation ...
STAT
2d
A radiopharmaceuticals startup raises $175 million
RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
COPD
Sanofi
Regeneron
China
United States
Feedback